236 related articles for article (PubMed ID: 19381453)
1. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Kelly K; Swords R; Mahalingam D; Padmanabhan S; Giles FJ
Target Oncol; 2009 Apr; 4(2):99-105. PubMed ID: 19381453
[TBL] [Abstract][Full Text] [Related]
2. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Breccia M; Alimena G
Expert Opin Drug Saf; 2010 Sep; 9(5):713-21. PubMed ID: 20722490
[TBL] [Abstract][Full Text] [Related]
3. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Wei G; Rafiyath S; Liu D
J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
[TBL] [Abstract][Full Text] [Related]
5. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.
Eskazan AE; Soysal T; Ongoren S; Gulturk E; Ferhanoglu B; Aydin Y
Haematologica; 2011 Mar; 96(3):e15; author reply e16-7. PubMed ID: 21357709
[No Abstract] [Full Text] [Related]
6. Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
Nagata Y; Fukuda S; Kobayashi T; Yamashita T; Ohashi K; Sakamaki H; Akiyama H
Int J Hematol; 2010 Apr; 91(3):539-41. PubMed ID: 20191333
[TBL] [Abstract][Full Text] [Related]
7. [Management of chronic myeloid leukemia].
Kubuki Y
Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
[No Abstract] [Full Text] [Related]
8. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Jabbour E; Deininger M; Hochhaus A
Leukemia; 2011 Feb; 25(2):201-10. PubMed ID: 20861918
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia: advances in diagnosis and management.
Noronha S; Sawyer S
JAAPA; 2013 Feb; 26(2):26-9. PubMed ID: 23409382
[No Abstract] [Full Text] [Related]
11. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Thienelt CD; Green K; Bowles DW
Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
[TBL] [Abstract][Full Text] [Related]
12. Pleural effusions due to dasatinib.
Brixey AG; Light RW
Curr Opin Pulm Med; 2010 Jul; 16(4):351-6. PubMed ID: 20375898
[TBL] [Abstract][Full Text] [Related]
13. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
Masiello D; Gorospe G; Yang AS
J Hematol Oncol; 2009 Nov; 2():46. PubMed ID: 19909541
[TBL] [Abstract][Full Text] [Related]
14. Oral BMS-354825 rescues Gleevec-resistant CML.
Cancer Biol Ther; 2004 Aug; 3(8):700. PubMed ID: 15751154
[No Abstract] [Full Text] [Related]
15. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.
Steegmann JL; Cervantes F; le Coutre P; Porkka K; Saglio G
Leuk Lymphoma; 2012 Dec; 53(12):2351-61. PubMed ID: 22616642
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Schiffer CA
N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
[No Abstract] [Full Text] [Related]
17. The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
Visani G; Breccia M; Montefusco E; Morra E; Santini V; Isidori A
Haematologica; 2011 Apr; 96(4):e23-4; author reply e25. PubMed ID: 21454871
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Cortes J; Kim DW; Raffoux E; Martinelli G; Ritchie E; Roy L; Coutre S; Corm S; Hamerschlak N; Tang JL; Hochhaus A; Khoury HJ; Brümmendorf TH; Michallet M; Rege-Cambrin G; Gambacorti-Passerini C; Radich JP; Ernst T; Zhu C; Van Tornout JM; Talpaz M
Leukemia; 2008 Dec; 22(12):2176-83. PubMed ID: 18754032
[TBL] [Abstract][Full Text] [Related]
19. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Quintás-Cardama A; Cortés JE; Kantarjian H
Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S82-8. PubMed ID: 19254885
[TBL] [Abstract][Full Text] [Related]
20. [Clinical progress in chronic myelogenous leukemia].
Matsunaga T
Rinsho Ketsueki; 2009 Oct; 50(10):1489-99. PubMed ID: 19915358
[No Abstract] [Full Text] [Related]
[Next] [New Search]